Literature DB >> 28181816

Induction of Oxidants Distinguishes Susceptibility of Prostate Carcinoma Cell Lines to p53 Gene Transfer Mediated by an Improved Adenoviral Vector.

Rodrigo Esaki Tamura1, Aline Hunger1, Denise C Fernandes2, Francisco R Laurindo2, Eugenia Costanzi-Strauss3, Bryan E Strauss1.   

Abstract

Previously, the authors developed an adenoviral vector, Ad-PG, where transgene expression is regulated by a p53-responsive promoter. When used to transfer the p53 cDNA, a positive feedback mechanism is established. In the present study, a critical comparison is performed between Ad-PGp53 and AdRGD-PGp53, where the RGD motif was incorporated in the adenoviral fiber protein. AdRGD-PGp53 provided superior transgene expression levels and resulted in the killing of prostate carcinoma cell lines DU145 and PC3. In vitro, this effect was associated with increased production of cytoplasmic and mitochondrial oxidants, DNA damage as revealed by detection of phosphorylated H2AX, as well as cell death consistent with apoptosis. Differential gene expression of key mediators of reactive oxygen species pathways was also observed. Specifically, it was noted that induction of known p53-target genes Sestrin2 and PIG3, as well as a novel target, NOX1, occurred in PC3 cells only when transduced with the improved vector, AdRGD-PGp53. The participation of NOX1 was confirmed upon its inhibition using a specific peptide, resulting in reduced cell death. In situ gene therapy also resulted in significantly improved inhibition of tumor progression consistent with oxidant-induced DNA damage only when treated with the novel AdRGD-PGp53 vector. The study shows that the improved adenovirus overcomes limitations associated with other p53-expressing vectors and induces oxidant-mediating killing, thus supporting its further development for cancer gene therapy.

Entities:  

Keywords:  NOX1; adenovirus; oxidants/ROS; p53; prostate carcinoma

Mesh:

Substances:

Year:  2017        PMID: 28181816     DOI: 10.1089/hum.2016.139

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  10 in total

1.  Combination of cabazitaxel and p53 gene therapy abolishes prostate carcinoma tumor growth.

Authors:  Rodrigo Esaki Tamura; Marlous G Lana; Eugenia Costanzi-Strauss; Bryan E Strauss
Journal:  Gene Ther       Date:  2019-03-29       Impact factor: 5.250

2.  Post-exposure immunization by capsid-modified AdC7 vector expressing Pseudomonas aeruginosa OprF clears P. aeruginosa respiratory infection.

Authors:  Rika Gomi; Anurag Sharma; Wenzhu Wu; Biin Sung; Stefan Worgall
Journal:  Vaccine       Date:  2017-11-07       Impact factor: 3.641

3.  Exploration of p53 plus interferon-beta gene transfer for the sensitization of human colorectal cancer cell lines to cell death.

Authors:  Paulo Roberto Del Valle; Samir Andrade Mendonça; Fernanda Antunes; Aline Hunger; Rodrigo E Tamura; Daniela Bertolini Zanatta; Bryan E Strauss
Journal:  Cancer Biol Ther       Date:  2021-04-14       Impact factor: 4.742

Review 4.  A Mini-Review of Reactive Oxygen Species in Urological Cancer: Correlation with NADPH Oxidases, Angiogenesis, and Apoptosis.

Authors:  Yasuyoshi Miyata; Tomohiro Matsuo; Yuji Sagara; Kojiro Ohba; Kaname Ohyama; Hideki Sakai
Journal:  Int J Mol Sci       Date:  2017-10-22       Impact factor: 5.923

Review 5.  p53 and metabolism: from mechanism to therapeutics.

Authors:  Fernando M Simabuco; Mirian G Morale; Isadora C B Pavan; Ana P Morelli; Fernando R Silva; Rodrigo E Tamura
Journal:  Oncotarget       Date:  2018-05-04

Review 6.  Improving adenoviral vectors and strategies for prostate cancer gene therapy.

Authors:  Rodrigo Esaki Tamura; Igor Vieira de Luna; Marlous Gomes Lana; Bryan E Strauss
Journal:  Clinics (Sao Paulo)       Date:  2018-08-20       Impact factor: 2.365

Review 7.  Drugging p53 in cancer: one protein, many targets.

Authors:  Ori Hassin; Moshe Oren
Journal:  Nat Rev Drug Discov       Date:  2022-10-10       Impact factor: 112.288

8.  The use of adenoviral vectors in gene therapy and vaccine approaches.

Authors:  Natália Meneses Araújo; Ileana Gabriela Sanchez Rubio; Nicholas Pietro Agulha Toneto; Mirian Galliote Morale; Rodrigo Esaki Tamura
Journal:  Genet Mol Biol       Date:  2022-10-07       Impact factor: 2.087

9.  Response of human melanoma cell lines to interferon-beta gene transfer mediated by a modified adenoviral vector.

Authors:  Taynah I P David; Otto L D Cerqueira; Marlous G Lana; Ruan F V Medrano; Aline Hunger; Bryan E Strauss
Journal:  Sci Rep       Date:  2020-10-21       Impact factor: 4.379

10.  Combined p14ARF and Interferon-β Gene Transfer to the Human Melanoma Cell Line SK-MEL-147 Promotes Oncolysis and Immune Activation.

Authors:  Otto Luiz Dutra Cerqueira; Maria Alejandra Clavijo-Salomon; Elaine Cristina Cardoso; Tharcisio Citrangulo Tortelli Junior; Samir Andrade Mendonça; José Alexandre M Barbuto; Bryan E Strauss
Journal:  Front Immunol       Date:  2020-10-22       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.